Compare J M Smucker Co (SJM) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Tempus AI — how do they compare? J M Smucker Co trades at $123.61 (market cap $13.32B), while Tempus AI trades at $61.13 (market cap $11.67B). The key difference: J M Smucker Co and Tempus AI are close in size by market cap, and J M Smucker Co pays a 3.59% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| SJM | TEM | |
|---|---|---|
Market Cap | $13.32B | $11.67B |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $132.34 | $103.25 |
52-Week Low | $89.53 | $41.55 |
Enterprise Value | $20.17B | $12.30B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal per moving averages despite oscillators showing bearish momentum. The company reported strong Q1 2027 earnings, beating estimates with EPS of $3.24, and raised full-year guidance. Valuation metrics include a P/E of 58.25 and P/S of 1.45, while recent news highlights CEO and CFO stock sales and positive analyst sentiment.
Outlook is positive with a consensus price target of $144.78, implying 16% upside, supported by earnings momentum and dividend yield. Risks include high debt levels, with debt-to-asset ratio at 43.71% in 2025, and volatile net income margins, which turned negative in 2025. Investors should weigh strong recent performance against financial leverage and insider selling activity.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
